TrialScope is part of Informa Pharma Intelligence, a division of Informa Business Intelligence, Inc. (IBI). IBI is a wholly-owned subsidiary of Informa PLC.

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Top 5 Global Clinical Trial Disclosure Changes in 2020 Amidst Pandemic

Thomas Wicks

December 16, 2020

As seen on Applied Clinical Trials – Posted Dec. 16, 2020 – Original Article

Dec. 16, 2020 | Spotlight on clinical trials created by COVID-19 pandemic has forced regulatory officials around the world to expand disclosure requirements on results.

Thomas Wicks, chief strategy officer for TrialScope, notes that this year has been a busy one in the clinical trial disclosure and transparency space. The coronavirus pandemic has encouraged the rapid sharing of clinical data at a speed and scope that well exceeds regulatory requirements.

Continued on Applied Clinical Trials

About the author

Thomas is responsible for tracking regulatory and market trends that shape TrialScope’s clinical trial disclosure and transparency solutions. He has more than 23 years of experience with performance and content management solutions, specializing in applications for life sciences such as clinical trial disclosure, structured product labeling and submissions management. Thomas has been focused on trial transparency since 2007.